ABION Inc. (KOSDAQ:203400)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,910.00
-160.00 (-2.26%)
At close: Apr 25, 2025, 3:30 PM KST
-9.44%
Market Cap 185.28B
Revenue (ttm) 759.68M
Net Income (ttm) -43.38B
Shares Out 28.64M
EPS (ttm) -1,800.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100,875
Average Volume 97,999
Open 7,100.00
Previous Close 7,070.00
Day's Range 6,910.00 - 7,150.00
52-Week Range 5,240.00 - 13,000.00
Beta 1.01
RSI 47.42
Earnings Date May 15, 2025

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 203400
Full Company Profile

Financial Performance

In 2024, ABION's revenue was 759.68 million, a decrease of -40.38% compared to the previous year's 1.27 billion. Losses were -43.38 billion, 48.5% more than in 2023.

Financial Statements

News

There is no news available yet.